Autosomal recessive nonsyndromic hearing loss 97
disease diseaseOn this page
Also known as autosomal recessive deafness 97autosomal recessive nonsyndromic deafness 97autosomal recessive nonsyndromic deafness caused by mutation in METautosomal recessive nonsyndromic deafness type 97deafness, autosomal recessive 97deafness, autosomal recessive type 97DFNB97MET autosomal recessive nonsyndromic deafness
Summary
Autosomal recessive nonsyndromic hearing loss 97 (MONDO:0014739) is a disease caused by MET (GenCC Strong), with 1 cohort gene.
At a glance
- Causal gene: MET (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 267
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | autosomal recessive nonsyndromic hearing loss 97 |
| Mondo ID | MONDO:0014739 |
| OMIM | 616705 |
| DOID | DOID:0110539 |
| UMLS | C4084709 |
| MedGen | 899875 |
| GARD | 0022655 |
| Is cancer (heuristic) | no |
Also known as: autosomal recessive deafness 97 · autosomal recessive nonsyndromic deafness 97 · autosomal recessive nonsyndromic deafness caused by mutation in MET · autosomal recessive nonsyndromic deafness type 97 · deafness, autosomal recessive 97 · deafness, autosomal recessive type 97 · DFNB97 · MET autosomal recessive nonsyndromic deafness
Data availability: 267 ClinVar variants · 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › hearing loss, autosomal recessive › autosomal recessive nonsyndromic hearing loss 97
Related subtypes (101): autosomal recessive nonsyndromic hearing loss 5, autosomal recessive nonsyndromic hearing loss 1A, autosomal recessive nonsyndromic hearing loss 2, autosomal recessive nonsyndromic hearing loss 3, autosomal recessive nonsyndromic hearing loss 4, autosomal recessive nonsyndromic hearing loss 6, autosomal recessive nonsyndromic hearing loss 7, autosomal recessive nonsyndromic hearing loss 9, autosomal recessive nonsyndromic hearing loss 8, autosomal recessive nonsyndromic hearing loss 12, autosomal recessive nonsyndromic hearing loss 15, autosomal recessive nonsyndromic hearing loss 18A, autosomal recessive nonsyndromic hearing loss 17, autosomal recessive nonsyndromic hearing loss 13, autosomal recessive nonsyndromic hearing loss 21, autosomal recessive nonsyndromic hearing loss 14, autosomal recessive nonsyndromic hearing loss 16, autosomal recessive nonsyndromic hearing loss 20, autosomal recessive nonsyndromic hearing loss 26, autosomal recessive nonsyndromic hearing loss 27, autosomal recessive nonsyndromic hearing loss 22, autosomal recessive nonsyndromic hearing loss 31, autosomal recessive nonsyndromic hearing loss 30, autosomal recessive nonsyndromic hearing loss 33, autosomal recessive nonsyndromic hearing loss 37, autosomal recessive nonsyndromic hearing loss 38, autosomal recessive nonsyndromic hearing loss 40, autosomal recessive nonsyndromic hearing loss 39, autosomal recessive nonsyndromic hearing loss 35, autosomal recessive nonsyndromic hearing loss 32, autosomal recessive nonsyndromic hearing loss 36, autosomal recessive nonsyndromic hearing loss 48, autosomal recessive nonsyndromic hearing loss 23, autosomal recessive nonsyndromic hearing loss 42, autosomal recessive nonsyndromic hearing loss 46, autosomal recessive nonsyndromic hearing loss 53, autosomal recessive nonsyndromic hearing loss 28, autosomal recessive nonsyndromic hearing loss 51, autosomal recessive nonsyndromic hearing loss 47, autosomal recessive nonsyndromic hearing loss 55, autosomal recessive nonsyndromic hearing loss 62, autosomal recessive nonsyndromic hearing loss 49, autosomal recessive nonsyndromic hearing loss 44, autosomal recessive nonsyndromic hearing loss 66, autosomal recessive nonsyndromic hearing loss 59, autosomal recessive nonsyndromic hearing loss 65, autosomal recessive nonsyndromic hearing loss 67, autosomal recessive nonsyndromic hearing loss 68, autosomal recessive nonsyndromic hearing loss 24, autosomal recessive nonsyndromic hearing loss 63, autosomal recessive nonsyndromic hearing loss 45, autosomal recessive nonsyndromic hearing loss 1B, autosomal recessive nonsyndromic hearing loss 71, autosomal recessive nonsyndromic hearing loss 77, autosomal recessive nonsyndromic hearing loss 25, autosomal recessive nonsyndromic hearing loss 79, autosomal recessive nonsyndromic hearing loss 84A, autosomal recessive nonsyndromic hearing loss 85, autosomal recessive nonsyndromic hearing loss 91, autosomal recessive nonsyndromic hearing loss 83, autosomal recessive nonsyndromic hearing loss 74, autosomal recessive nonsyndromic hearing loss 61, autosomal recessive nonsyndromic hearing loss 89, autosomal recessive nonsyndromic hearing loss 29, autosomal recessive nonsyndromic hearing loss 96, autosomal recessive nonsyndromic hearing loss 86, autosomal recessive nonsyndromic hearing loss 98, autosomal recessive nonsyndromic hearing loss 93, autosomal recessive nonsyndromic hearing loss 70, autosomal recessive nonsyndromic hearing loss 84B, autosomal recessive nonsyndromic hearing loss 18B, autosomal recessive nonsyndromic hearing loss 88, autosomal recessive nonsyndromic hearing loss 76, autosomal recessive nonsyndromic hearing loss 101, autosomal recessive nonsyndromic hearing loss 102, autosomal recessive nonsyndromic hearing loss 103, autosomal recessive nonsyndromic hearing loss 104, hearing loss, autosomal recessive 111, hearing loss, autosomal recessive 118, with cochlear aplasia, hearing loss, autosomal recessive 119, hearing loss, autosomal recessive 117, hearing loss, autosomal recessive 112, hearing loss, autosomal recessive 113, hearing loss, autosomal recessive 100, hearing loss, autosomal recessive 94, hearing loss, autosomal recessive 114, hearing loss, autosomal recessive 115, hearing loss, autosomal recessive 99, hearing loss, autosomal recessive 106, hearing loss, autosomal recessive 107, hearing loss, autosomal recessive 108, hearing loss, autosomal recessive 57, hearing loss, autosomal recessive 109, hearing loss, autosomal recessive 116, hearing loss, autosomal recessive 110, hearing loss, autosomal recessive 120, hearing loss, autosomal recessive 121, hearing loss, autosomal recessive 122, hearing loss, autosomal recessive 123, autosomal recessive nonsyndromic hearing loss 124, hearing loss, autosomal recessive 125
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
267 retrieved; paginated sample, class counts are floors:
130 uncertain significance, 124 conflicting classifications of pathogenicity, 6 benign, 5 benign/likely benign, 1 pathogenic/likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 13887 | NM_000245.4(MET):c.3281A>G (p.His1094Arg) | MET | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 183686 | NM_000245.4(MET):c.2521T>G (p.Phe841Val) | MET | Pathogenic | criteria provided, single submitter |
| 1021858 | NM_000245.4(MET):c.3403A>T (p.Ser1135Cys) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1320342 | NM_000245.4(MET):c.617T>C (p.Phe206Ser) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 132694 | NM_000245.4(MET):c.1039G>A (p.Ala347Thr) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 134654 | NM_000245.4(MET):c.1771C>T (p.Arg591Trp) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 135966 | NM_000245.4(MET):c.3218C>T (p.Pro1073Leu) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 135968 | NM_000245.4(MET):c.4007G>A (p.Arg1336Gln) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 135974 | NM_000245.4(MET):c.65G>T (p.Ser22Ile) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 135975 | NM_000245.4(MET):c.689C>T (p.Thr230Met) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1388673 | NM_000245.4(MET):c.2588A>G (p.Asn863Ser) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 142059 | NM_000245.4(MET):c.406G>A (p.Val136Ile) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 142060 | NM_000245.4(MET):c.2543T>C (p.Val848Ala) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1429037 | NM_000245.4(MET):c.1347C>A (p.Asp449Glu) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1438566 | NM_000245.4(MET):c.2555T>C (p.Met852Thr) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1447271 | NM_000245.4(MET):c.229G>A (p.Asp77Asn) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1505421 | NM_000245.4(MET):c.2662C>G (p.His888Asp) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 167292 | NM_000245.4(MET):c.901A>G (p.Thr301Ala) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1692567 | NM_000245.4(MET):c.62G>A (p.Arg21Lys) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1734426 | NM_000245.4(MET):c.3682G>T (p.Asp1228Tyr) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1776377 | NM_000245.4(MET):c.1610A>G (p.Gln537Arg) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1784380 | NM_000245.4(MET):c.200C>A (p.Thr67Asn) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 184358 | NM_000245.4(MET):c.1669A>G (p.Thr557Ala) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 184359 | NM_000245.4(MET):c.146A>G (p.Glu49Gly) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 185464 | NM_000245.4(MET):c.2278A>G (p.Ile760Val) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 185606 | NM_000245.4(MET):c.1081G>T (p.Ala361Ser) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 186678 | NM_000245.4(MET):c.2825C>T (p.Ser942Leu) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 187360 | NM_000245.4(MET):c.2455G>A (p.Ala819Thr) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 188112 | NM_000245.4(MET):c.40C>T (p.Leu14Phe) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 188184 | NM_000245.4(MET):c.2909G>A (p.Arg970His) | MET | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 14 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| MET | Strong | Autosomal recessive | autosomal recessive nonsyndromic hearing loss 97 | 14 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| MET | Orphanet:319298 | Papillary renal cell carcinoma |
| MET | Orphanet:33402 | Pediatric hepatocellular carcinoma |
| MET | Orphanet:47044 | Hereditary papillary renal cell carcinoma |
| MET | Orphanet:488265 | Osteofibrous dysplasia |
| MET | Orphanet:90636 | Rare autosomal recessive non-syndromic sensorineural deafness type DFNB |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| MET | HGNC:7029 | ENSG00000105976 | P08581 | Hepatocyte growth factor receptor | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| MET | Hepatocyte growth factor receptor | Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. |
Protein-family classification
Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Kinase | 1 | 27.7× | 0.036 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| MET | Kinase | yes | 2.7.10.1 | Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Semap_dom |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| cartilage tissue | 1 |
| germinal epithelium of ovary | 1 |
| pigmented layer of retina | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| MET | 270 | ubiquitous | marker | pigmented layer of retina, germinal epithelium of ovary, cartilage tissue |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| MET | 5,823 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| MET | P08581 | 130 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 44. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Drug-mediated inhibition of MET activation | 1 | 5710.0× | 0.004 | MET |
| MET activates STAT3 | 1 | 3806.7× | 0.004 | MET |
| MET activates PTPN11 | 1 | 2284.0× | 0.004 | MET |
| MET interacts with TNS proteins | 1 | 2284.0× | 0.004 | MET |
| MET Receptor Activation | 1 | 1903.3× | 0.004 | MET |
| MET activates PI3K/AKT signaling | 1 | 1903.3× | 0.004 | MET |
| Sema4D mediated inhibition of cell attachment and migration | 1 | 1427.5× | 0.004 | MET |
| MET receptor recycling | 1 | 1142.0× | 0.004 | MET |
| MET activates RAS signaling | 1 | 1038.2× | 0.004 | MET |
| MET activates RAP1 and RAC1 | 1 | 1038.2× | 0.004 | MET |
| Listeria monocytogenes entry into host cells | 1 | 1038.2× | 0.004 | MET |
| InlB-mediated entry of Listeria monocytogenes into host cell | 1 | 761.3× | 0.005 | MET |
| Sema4D in semaphorin signaling | 1 | 671.8× | 0.005 | MET |
| MET promotes cell motility | 1 | 601.0× | 0.005 | MET |
| MECP2 regulates neuronal receptors and channels | 1 | 601.0× | 0.005 | MET |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 1 | 571.0× | 0.005 | MET |
| Negative regulation of MET activity | 1 | 519.1× | 0.005 | MET |
| Semaphorin interactions | 1 | 393.8× | 0.006 | MET |
| MET activates PTK2 signaling | 1 | 380.7× | 0.006 | MET |
| PI3K/AKT Signaling in Cancer | 1 | 368.4× | 0.006 | MET |
| Bacterial Infection Pathways | 1 | 335.9× | 0.006 | MET |
| Signaling by MET | 1 | 317.2× | 0.006 | MET |
| Transcriptional Regulation by MECP2 | 1 | 317.2× | 0.006 | MET |
| Negative regulation of the PI3K/AKT network | 1 | 278.5× | 0.007 | MET |
| MITF-M-dependent gene expression | 1 | 181.3× | 0.010 | MET |
| MAPK1/MAPK3 signaling | 1 | 131.3× | 0.013 | MET |
| Constitutive Signaling by Aberrant PI3K in Cancer | 1 | 126.9× | 0.013 | MET |
| MITF-M-regulated melanocyte development | 1 | 114.2× | 0.014 | MET |
| MAPK family signaling cascades | 1 | 102.9× | 0.015 | MET |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 1 | 96.8× | 0.015 | MET |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| negative regulation of hydrogen peroxide-mediated programmed cell death | 1 | 4213.0× | 0.003 | MET |
| hepatocyte growth factor receptor signaling pathway | 1 | 2106.5× | 0.003 | MET |
| endothelial cell morphogenesis | 1 | 1053.2× | 0.003 | MET |
| positive regulation of endothelial cell chemotaxis | 1 | 991.3× | 0.003 | MET |
| positive chemotaxis | 1 | 802.5× | 0.003 | MET |
| branching morphogenesis of an epithelial tube | 1 | 732.7× | 0.003 | MET |
| pancreas development | 1 | 674.1× | 0.003 | MET |
| excitatory postsynaptic potential | 1 | 443.5× | 0.004 | MET |
| semaphorin-plexin signaling pathway | 1 | 401.2× | 0.004 | MET |
| negative regulation of autophagy | 1 | 259.3× | 0.006 | MET |
| liver development | 1 | 221.7× | 0.006 | MET |
| cell surface receptor protein tyrosine kinase signaling pathway | 1 | 173.7× | 0.007 | MET |
| neuron differentiation | 1 | 100.3× | 0.012 | MET |
| cell surface receptor signaling pathway | 1 | 64.1× | 0.017 | MET |
| positive regulation of transcription by RNA polymerase II | 1 | 14.9× | 0.067 | MET |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| MET | AFATINIB |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| MET | 95 | 4 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| AFATINIB | 4 | MET |
| FEDRATINIB | 4 | MET |
| TIVOZANIB | 4 | MET |
| AXITINIB | 4 | MET |
| SORAFENIB | 4 | MET |
| NERATINIB | 4 | MET |
| INFIGRATINIB PHOSPHATE | 4 | MET |
| INFIGRATINIB | 4 | MET |
| PALBOCICLIB | 4 | MET |
| ENTRECTINIB | 4 | MET |
| DABRAFENIB | 4 | MET |
| CABOZANTINIB S-MALATE | 4 | MET |
| AFATINIB DIMALEATE | 4 | MET |
| CABOZANTINIB | 4 | MET |
| CERITINIB | 4 | MET |
| VANDETANIB | 4 | MET |
| BOSUTINIB | 4 | MET |
| CAPMATINIB | 4 | MET |
| TEPOTINIB | 4 | MET |
| BRIGATINIB | 4 | MET |
| ENSARTINIB | 4 | MET |
| PAZOPANIB | 4 | MET |
| NINTEDANIB | 4 | MET |
| SUNITINIB | 4 | MET |
| ERLOTINIB | 4 | MET |
| CRIZOTINIB | 4 | MET |
| MIDOSTAURIN | 4 | MET |
| GEFITINIB | 4 | MET |
| LINSITINIB | 3 | MET |
| RIGOSERTIB | 3 | MET |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 1.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| MET | 2,015 | Binding:2005, Functional:6, ADMET:4 |
Cohort enzymes (BRENDA EC)
| Symbol | EC numbers | Names |
|---|---|---|
| MET | 2.7.10.1 | receptor protein-tyrosine kinase |
Cohort genes with high screening signal
≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.
| Symbol | ChEMBL assays |
|---|---|
| MET | 2,015 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| AFATINIB | 4 | MET |
| FEDRATINIB | 4 | MET |
| TIVOZANIB | 4 | MET |
| AXITINIB | 4 | MET |
| SORAFENIB | 4 | MET |
| NERATINIB | 4 | MET |
| INFIGRATINIB PHOSPHATE | 4 | MET |
| INFIGRATINIB | 4 | MET |
| PALBOCICLIB | 4 | MET |
| ENTRECTINIB | 4 | MET |
| DABRAFENIB | 4 | MET |
| CABOZANTINIB S-MALATE | 4 | MET |
| AFATINIB DIMALEATE | 4 | MET |
| CABOZANTINIB | 4 | MET |
| CERITINIB | 4 | MET |
| VANDETANIB | 4 | MET |
| BOSUTINIB | 4 | MET |
| CAPMATINIB | 4 | MET |
| TEPOTINIB | 4 | MET |
| BRIGATINIB | 4 | MET |
| ENSARTINIB | 4 | MET |
| PAZOPANIB | 4 | MET |
| NINTEDANIB | 4 | MET |
| SUNITINIB | 4 | MET |
| ERLOTINIB | 4 | MET |
| CRIZOTINIB | 4 | MET |
| MIDOSTAURIN | 4 | MET |
| GEFITINIB | 4 | MET |
| LINSITINIB | 3 | MET |
| RIGOSERTIB | 3 | MET |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | MET |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: MET